GlobeNewswire by notified

Ad hoc announcement: GAM Holding AG provides an update on full year 2022 results and change of date for results presentation to 25 April 2023

Share

25 January 2023

PRESS RELEASE

Ad hoc announcement pursuant to Art. 53 listing rules:


GAM Holding AG provides an update on full year 2022 results and change of date for results presentation to 25 April 2023

GAM today provides an update in accordance with its obligations under the listing rules of the SIX Swiss Exchange (article 53), in relation to the Group’s expected results for the full year 2022.

The Group expects to report an underlying loss before tax of approximately CHF 42.8 million for the full year 2022. This compares to a CHF 9.6 million underlying loss before tax for the full year 2021.

The Group also expects to report an IFRS net loss after tax of approximately CHF 309.9 million for the full year 2022. This compares to an IFRS net loss after tax of CHF 23.3 million for the full year 2021. On 3 August 2022 we had already communicated an IFRS loss of CHF 275.2 million for the half year 2022.

The annual results presentation for 2022 will now take place on 25 April 2023.

Performance

Notwithstanding the disappointing financial result in the context of very difficult 2022 markets and GAM experiencing net negative asset flows in common with much of the industry, we continue to position the firm strategically for the future.

  • Investment performance was strong with seven out of our 13 largest strategies being ranked top decile over three years, with a further two top quintile within their Morningstar peer groups; overall 66% of our fund assets under management outperformed their Morningstar peer group.
  • We have delivered on our cost saving targets. Total expenses for the full year 2022 were over CHF 20 million lower than 2021; year-end headcount was 11% lower than at the end of 2021.

Strategic update and revised date for full year results presentation

  • The Board of Directors is constantly reviewing the progress of the firm to ensure that our strategy is appropriate and in the interests of all our stakeholders. We are planning to provide an update on this review as part of the year end results communications.
  • In order to give us the necessary time to prepare this update, we have decided to reschedule the results presentation and publication of the annual report to 25 April 2023. This will include the interim management statement for the first quarter.
  • The AGM will be held in Zurich on 25 May 2023.

Jacqui Irvine appointed as Vice Chair

  • Following the planned retirement of Benjamin Meuli at the end of 2022, existing Board of Directors member, Jacqui Irvine has been appointed Vice Chair.

David Jacob, Chairman of GAM Holding AG, said: “2022 was a challenging year with our financial results seeing the impact from a market-led decline in our assets under management. However, Peter Sanderson has led a team which has delivered strong investment performance for our clients and material progress in simplifying the business, driving further efficiencies and delivering against our cost targets. The Board is working tirelessly to ensure that the firm is strategically positioned in the best interests of all our stakeholders and for this reason we have decided to delay our results presentation in order to be able to provide a more informative update on our progress”.

Upcoming events:

25 April 2023        Full year results 2022 / Q1 2023 Interim management statement
25May2023        Annual General Meeting

For further information please contact:

Charles Naylor         
Global Head of Communications and Investor Relations
T +44 7890 386 699

Media Relations        
Ute Dehn Christen        
T +41 58 426 31 36        

Visit us: www.gam.com
Follow us: Twitter and LinkedIn

About GAM

We are an active, independent global asset manager that thinks beyond the obvious to deliver distinctive and differentiated investment solutions for our clients across our three core businesses: Investment Management, Wealth Management and Fund Management Services.
Our purpose is to protect and enhance our clients’ financial future. We attract and empower the brightest minds to provide investment leadership, innovation and a positive impact on society and the environment.
Servicing institutions, financial intermediaries, and private investors, we manage CHF 74.6 billion of assets as of 30 September 2022.
Headquartered in Zurich, GAM Investments is listed on the SIX Swiss Exchange with the symbol ‘GAM’ and we employ 594 people across 14 countries with investment centres in London, Cambridge, Zurich, Hong Kong, New York and Milan, as at 30 June 2022. Our operational centres are in Dublin, Luxembourg, and London.

Disclaimer regarding forward-looking statements

This press release by GAM Holding AG (‘the Company’) includes forward-looking statements that reflect the Company’s intentions, beliefs or current expectations and projections about the Company’s future results of operations, financial condition, liquidity, performance, prospects, strategies, opportunities, and the industry in which it operates. Forward-looking statements involve all matters that are not historical facts. The Company has tried to identify those forward-looking statements by using words such as ‘may’, ‘will’, ‘would’, ‘should’, ‘expect’, ‘intend’, ‘estimate’, ‘anticipate’, ‘project’, ‘believe’, ‘seek’, ‘plan’, ‘predict’, ‘continue’ and similar expressions. Such statements are made on the basis of assumptions and expectations which, although the Company believes them to be reasonable at this time, may prove to be erroneous.

These forward-looking statements are subject to risks, uncertainties, assumptions, and other factors that could cause the Company’s actual results of operations, financial condition, liquidity, performance, prospects, or opportunities, as well as those of the markets it serves or intends to serve, to differ materially from those expressed in, or suggested by, these forward-looking statements. Important factors that could cause those differences include, but are not limited to: changing business or other market conditions, legislative, fiscal and regulatory developments, general economic conditions, and the Company’s ability to respond to trends in the financial services industry. Additional factors could cause actual results, performance or achievements to differ materially. The Company expressly disclaims any obligation or undertaking to release any update of, or revisions to, any forward-looking statements in this press release and any change in the Company’s expectations or any change in events, conditions or circumstances on which these forward-looking statements are based, except as required by applicable law or regulation.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Merus Announces Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting24.4.2024 16:00:00 CEST | Press release

Petosemtamab in combination with pembrolizumab in 1L HNSCC initial interim clinical data selected for rapid oral session presentation MCLA-145 as monotherapy or in combination with pembrolizumab in solid tumors initial interim clinical data selected for rapid oral session presentation MCLA-129 in NSCLC with c-MET exon 14 skipping mutations initial interim clinical data selected for poster presentation UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the acceptance of three abstracts for presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago, Illinois on May 31- June 4, 2024. Rapid oral presentation: Title: Petosemtamab (MCLA-158) with pembrolizumab as first-line (1L) treatment of recurrent/metastatic (r/m

Correction to stock exchange release: Siili Solutions Plc: Business review, 1 January – 31 March 202424.4.2024 15:55:00 CEST | Press release

Correction to stock exchange release: Siili Solutions Plc: Business review, 1 January – 31 March 2024 Siili Solutions Plc Stock exchange release 24 April 2024 at 16:55 This is a correction to the stock exchange release published by Siili Solutions Plc on 24 April 2024 at 9:45 am by which the company published its business review for the period 1 January – 31 March 2024. In section “Key events for January-March” it was stated that “75% of Siili employees have completed a GenAI certificate”. The correct information is that “51% of Siili employees in Finland have completed a GenAI certificate”. In addition, in the CEO review it was stated that “By the end of March, 75% of Siili’s employees in Finland had achieved the first-level certification.” The completion percentage was incorrect and the correct information is that “By the end of March, 51% of Siili’s employees in Finland had achieved the first-level certification.” The corrected release is stated below as a whole and the revised repo

Wereldhave announces reappointment of Supervisory Board member Hein Brand at Annual General Meeting of Shareholders24.4.2024 15:31:42 CEST | Press release

Wereldhave is pleased to announce the reappointment of Mr. Hein Brand as member of the Supervisory Board, as approved by the Annual General Meeting of shareholders (AGM) of Wereldhave N.V. In his role as Vice President of the Supervisory Board and Chairman of the Audit Committee, Mr Brand will continue to provide valuable leadership and guidance to the company for a period of two years, ending at the Annual General Meeting in April 2026. Full voting results of the Annual General Meeting will be published on the Company website. Attachment PB CORP 24-04-2024 - Wereldhave AGM reappoints Mr Hein Brand as Supervisory Board member

Leadership Evolution: Zafin Announces Strategic CEO Transition to Propel Future Growth24.4.2024 15:15:00 CEST | Press release

Al Karim Somji to Transition Leadership to Charbel Safadi as Part of Zafin's Long-Term Success Strategy VANCOUVER, British Columbia, April 24, 2024 (GLOBE NEWSWIRE) -- Zafin, the leading provider of SaaS core modernization and transformation solutions for banks, today announced a strategic leadership transition that has been part of the company’s long-term success plan. After more than two decades of exemplary leadership, Al Karim Somji will step down as Chief Executive Officer of Zafin. He will continue to serve as an ongoing member of the Board of Directors. As a founder of the Company, Al Karim has been pivotal in shaping Zafin's success, leaving a lasting legacy of excellence and innovation. Under his stewardship, Zafin has experienced significant growth and success, reinforcing its status as a leader in global banking technology. As an active board member and substantial owner, Al Karim will provide essential insight and guidance to ensure a smooth leadership transition. His exten

RenovaroCube to Acquire 100% Ownership of Cyclomics, Reinforcing Cutting-Edge Cancer Diagnostics Partnership24.4.2024 15:00:00 CEST | Press release

LOS ANGELES and AMSTERDAM, April 24, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (Nasdaq: RENB), a trailblazer in AI-driven early cancer diagnostics and therapeutics, and Cyclomics, a leader in ultra-sensitive 4th generation multi-omics molecular biology, proudly announce a significant milestone in their collaboration. RenovaroCube has entered into an amendment to its binding letter of intent to acquire 100% ownership of Cyclomics, further cementing their shared commitment to advancing state-of-the-art technologies in cancer diagnostics and treatment. Their combined relationships with Oxford Nanopore and Nvidia will further position RenovaroCube to be a leader in early cancer diagnostics and monitoring of treatment efficacy. Oxford Nanopore is a leader in sequencing technologies and Nvidia will provide vital super computing power and front edge software solutions such as Parabricks, BioNeMo, Monai and Nemo. Initially set at a 75% acquisition, this decision to acquire the remaining 25% of Cy

HiddenA line styled icon from Orion Icon Library.Eye